Key facts
- MediCrops’s last known valuation is $1.2B.
- It has raised $70.8M; the latest was Later Stage VC ($28.3M) in Nov 2024.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for MediCrops
- ·The full record, as it builds
Funding rounds
No funding rounds for MediCrops are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MediCrops
Developer of a digital healthcare ecosystem designed to improve patient care through regulated cannabinoid medicine and pharmaceutical services. The company offers telemedicine services, in-house R&D and production, and a licensed compounding pharmacy specializing in cannabinoid formulations, enabling patients across Switzerland and select EU countries to access personalized therapies with quality, speed, and regulatory certainty.
- Sector
- Healthcare
- HQ
- Pfaffikon, Switzerland
- Founded
- 2018
- Employees
- 53
- Website
- medicrops.com/
- Ownership
- Privately Held (backing)
MediCrops doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MediCrops shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MediCrops in its N-PORT filings yet. We sweep new filings monthly.